文献速递特殊人群用药治疗药物监测与药物基因组学

长效卡博特韦与利匹韦林妊娠期PBPK模拟

Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy.
PubMed 文献 · Br J Clin Pharmacol · 2024-02-10

研究利用生理药代动力学(PBPK)模型模拟妊娠期长效卡博特韦和利匹韦林获批方案的暴露。结果显示每月卡博特韦可维持目标浓度,每两月方案及利匹韦林方案在妊娠期可能无法充分维持抗病毒效力。

要点

  • 每月长效卡博特韦妊娠期Ctrough均高于664 ng/mL目标。
  • 每两月卡博特韦在妊娠晚期0.5%人群Ctrough低于目标。
  • 利匹韦林每月和每两月方案妊娠期Ctrough均可能不足。

核心结论

  • 模型预测每月长效卡博特韦可在整个妊娠期维持抗病毒效力,每两月方案需谨慎评估。
  • 每月和每两月长效利匹韦林在妊娠期可能无法充分维持抗病毒效力。

研究设计与样本

  • 成人PBPK模型经非妊娠成人临床数据验证后纳入妊娠期代谢与生理变化。
  • 妊娠PBPK模型经妊娠期口服利匹韦林和拉替拉韦数据验证。
  • 模拟不同妊娠期每月和每两月长效卡博特韦与利匹韦林12周处置及胎儿暴露。

主要发现

  • 每月卡博特韦第12周Ctrough在整个妊娠期高于664 ng/mL。
  • 每两月卡博特韦在妊娠晚期0.5%孕妇群体中Ctrough低于664 ng/mL。
  • 每月利匹韦林第12周Ctrough在至少40%孕妇中低于50 ng/mL。
  • 每两月利匹韦林第12周Ctrough在超过90%孕妇中低于50 ng/mL。
  • 38至40周脐带血与母血浓度比中位数:卡博特韦1.71(范围1.55-1.79),利匹韦林0.88(范围0.78-0.93)。

关键数值与推荐

  • 卡博特韦目标Ctrough为664 ng/mL,利匹韦林目标Ctrough为50 ng/mL。

临床怎么用

  • 妊娠期可考虑每月长效卡博特韦维持治疗,每两月方案需仔细临床评估。
  • 妊娠期使用长效利匹韦林方案可能需额外评估抗病毒效力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Long-acting cabotegravir and rilpivirine have been approved to manage HIV in adults, but data regarding safe use in pregnancy are limited. Physiologically-based pharmacokinetic (PBPK) modelling was used to simulate the approved dosing regimens in pregnancy and explore if Ctrough was maintained above cabotegravir and rilpivirine target concentrations (664 and 50 ng/mL, respectively). METHODS: An adult PBPK model was validated using clinical data of cabotegravir and rilpivirine in nonpregnant adults. This was modified by incorporating pregnancy-induced metabolic and physiological changes. The pregnancy PBPK model was validated with data on oral rilpivirine and raltegravir (UGT1A1 probe substrate) in pregnancy. Twelve weeks' disposition of monthly and bimonthly dosing of long-acting cabotegravir and rilpivirine was simulated at different trimesters and foetal exposure was also estimated. RESULTS: Predicted Ctrough at week 12 for monthly long-acting cabotegravir was above 664 ng/mL throughout pregnancy, but below the target in 0.5% of the pregnant population in the third trimester with bimonthly long-acting cabotegravir. Predicted Ctrough at week 12 for monthly and bimonthly long-acting rilpivirine was below 50 ng/mL in at least 40% and over 90% of the pregnant population, respectively, throughout pregnancy. Predicted medians (range) of cord-to-maternal blood ratios were 1.71 (range, 1.55-1.79) for cabotegravir and 0.88 (0.78-0.93) for rilpivirine between weeks 38 and 40. CONCLUSIONS: Model predictions suggest that monthly long-acting cabotegravir could maintain antiviral efficacy throughout pregnancy, but that bimonthly administration may require careful clinical evaluation. Both monthly and bimonthly long-acting rilpivirine may not adequately maintain antiviral efficacy in pregnancy.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Atoyebi S, Bunglawala F, Cottura N, et al. Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy. Br J Clin Pharmacol. 2024. PMID: 38340019. doi:10.1111/bcp.16006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。